Acambis plc, of Cambridge, UK, appointed Ross Graham independent nonexecutive director and chairman of the audit committee.
Advanced Viral Research Corp., of Yonkers, N.Y., appointed Carol Epstein acting medical director.
Advancis Pharmaceutical Corp., of Germantown, Md., appointed Barry Hafkin chief scientific officer.
Affymax Inc., of Palo Alto, Calif., appointed Douglas Cole vice president of development and Julie Iwashita director of clinical development.
Alantos Pharmaceuticals AG, of Heidelberg, Germany, appointed Keith Dionne chairman and CEO. Fritz Frickel will become executive vice president of research and development.
Alexion Pharmaceuticals Inc., of Cheshire, Conn., appointed Larry Mathis to its board.
Alltracel Pharmaceuticals plc, of Dublin, Ireland, appointed John Kelly head of alliances and acquisitions.
Ambit Biosciences, of San Diego, added Tony Hunter and Webster Cavenee to its scientific advisory board.
AtheroGenics Inc., of Atlanta, appointed Robert Ryan vice president of regulatory affairs.
AVI BioPharma Inc., of Portland, Ore., appointed Peter O'Hanley senior vice president of clinical development and regulatory affairs and Ray Cummings vice president of business development.
Axonyx Inc., of New York, appointed Ralph Snyderman to its board.
Barrier Therapeutics Inc., of Princeton, N.J., appointed Joan Chypyha general manager in Canada.
Bioanalytical Systems Inc., of West Lafayette, Ind., named Michael Cox vice president of finance, treasurer and chief financial officer.
BioGentech Corp., of Irvine, Calif., appointed Radul Radovich and Kevin Prendiville to its board.
Biopure Corp., of Cambridge, Mass., appointed Christopher Stevens vice president of clinical research.
Boston Biomedica Inc., of West Bridgewater, Mass., promoted Michael Avallone to chief financial officer.
Bruker Daltonics Inc., of Billerica, Mass., appointed Michael Schubert vice president of research and development.
C.E. Unterberg, Towbin, of New York, appointed Angela Larson managing director in the equity research department.
Calypte Biomedical Corp., of Alameda, Calif., appointed Maxim Soulimov to the board.
Chronogen Inc., of Montreal, appointed Louis Lamontagne to its board.
Compound Therapeutics Inc., of Waltham, Mass., appointed Alan Crane to its board. Patrick Gage will serve as executive chairman.
Corgentech Inc., of South San Francisco, appointed Thomas Yonker vice president of project and alliance management.
Cytogen Corp., of Princeton, N.J., appointed Thomas Lytle senior vice president of sales and marketing.
CytRx Corp., of Los Angeles, and its subsidiary, Araios Inc., appointed Tariq Rana to the scientific advisory board. CytRx also appointed Gregory Liberman general counsel and corporate secretary and Robert Brown to its board.
Genaera Corp., of Plymouth Meeting, Pa., appointed Roger Voegl acting chief medical officer.
Genentech Inc., of South San Francisco, promoted Todd Pierce to vice president of corporate information technology.
Gen-Probe Inc., of San Diego, appointed Mae Jemison to its board.
Gilead Sciences Inc., of Foster City, Calif., appointed Nicholas Moore to its board.